About Imbria Pharmaceuticals
Imbria Pharmaceuticals is a private company based in Boston, Massachusetts. It has reported $147,680,744 raised in three offerings on Form D since July 2018.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Mar 10, 2025 | Apr 1, 2025amended Dec 16, 2025 | $66,695,817of $144.1M target | 10 | $6.6M | EquityRule 506(b) | Form D/A ↗1 earlier filing |
| Jun 22, 2020 | Jul 2, 2020 | $40,734,932of $80.7M target | 4 | $10.1M | Equity, Securities on exerciseRule 506(b) | Form D ↗ |
| Jul 2, 2018 | Jul 9, 2018 | $40,249,995fully sold | 3 | $13.4M | EquityRule 506(b) | Form D ↗ |
| Total, three offerings | $147,680,744 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on Imbria Pharmaceuticals's Form D filed Dec 16, 2025.
PC
Pavan Cheruvu
Director
CD
Charles Dunn
Director
AS
Alvin Shih
Executive officer and director
LR
Luse Rebecca
Director
KH
Ken Horne
Director
Also a chief executive officer and director at Capacity Bio and a director at Pahr Therapeutics and Typewriter Therapeutics.
KJ
Komal Joshi
Secretary
AL
Andrew Levin
Director
Earlier filings also listed James Januzzi (director, last listed Jul 2020), David-Alexandre Gros (chief executive officer, last listed Jul 2020) and Pieter Boelhouwer (director, last listed Jul 2018).